These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 17021057)

  • 1. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
    Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
    Heyn K; Tredup A; Salvenmoser S; Müller FM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
    Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
    Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
    Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
    Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
    Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
    Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
    Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
    J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
    Peter J; Armstrong D; Lyman CA; Walsh TJ
    J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.